We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Mixed Results for GSK, Theravance’s COPD Therapy Relovair
Mixed Results for GSK, Theravance’s COPD Therapy Relovair
June 8, 2011
GlaxoSmithKline (GSK) and its partner Theravance recently announced the results of two studies of the companies’ chronic obstructive pulmonary disease (COPD) treatment Relovair which, though mixed, “support the continuation of the Relovair” program.